DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2195418/wall-street-analysts-think-adma-biologics-adma-is-a-good-investment-is-it?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2195418 Dec 08, 2023 - Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying? 0

https://www.zacks.com/stock/news/2195427/adm-adm-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2195427 Dec 08, 2023 - According to the average brokerage recommendation (ABR), one should invest in ADM (ADM). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.zacks.com/stock/news/2195361/what-makes-eyepoint-pharmaceuticals-eypt-a-good-fit-for-trend-investing?cid=CS-ZC-FT-tale_of_the_tape|recent_price_strength_screen-2195361 Dec 08, 2023 - If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. 0

https://www.fool.com/investing/2023/12/07/everyone-is-talking-about-tilray-brands-stock/?source=iedfolrf0000001 Dec 07, 2023 - Tilray's shift into making alcohol means that the vision for its future is now a lot bigger. 0

https://www.fool.com/investing/2023/12/07/c3ai-stock-earnings-report-the-good-and-the-bad/?source=iedfolrf0000001 Dec 07, 2023 - C3.ai revenue growth is back on track, but that track might be very short. 0

https://www.zacks.com/stock/news/2194749/crowdstrike-crwd-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2194749 Dec 07, 2023 - The average brokerage recommendation (ABR) for CrowdStrike (CRWD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? 0

https://www.zacks.com/stock/news/2194752/netflix-nflx-is-considered-a-good-investment-by-brokers-is-that-true?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2194752 Dec 07, 2023 - According to the average brokerage recommendation (ABR), one should invest in Netflix (NFLX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock? 0

https://www.cnbc.com/2023/12/07/op-ed-when-does-good-news-become-good-again-it-may-take-some-time.html Dec 07, 2023 - In recent years, stocks have had an inverse relationship with economic data. The better the numbers, the worse the market has performed. That could soon change. 0

https://www.fool.com/retirement/2023/12/07/medicare-advantage-enrollment-is-growing-but-is-th/?source=iedfolrf0000001 Dec 07, 2023 - Medicare Advantage plans are growing increasingly popular. But these plans come with several drawbacks that enrollees should know about. 0

https://www.zacks.com/stock/news/2194378/dick-s-sporting-goods-dks-is-up-12-16-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2194378 Dec 06, 2023 - Does Dick's Sporting Goods (DKS) have what it takes to be a top stock pick for momentum investors? Let's find out. 0